05/10/2023 - Press release
A study led by researchers at the Hospital del Mar Research Institute identifies that the deterioration of the blood-brain barrier, which regulates exchanges between the blood and the brain, can be used to identify which of these patients will have a more rapid progression. In the patients analysed, the risk of accelerated disease progression increases by 8% for every 10% increase in the level of albumin in cerebrospinal fluid and blood (a biomarker of damage to the blood-brain barrier). The results indicate that restoring the blood-brain barrier's ability to protect the brain could help slow the worsening of patients. This marker will allow a more accurate assessment of the prognosis of patients with cognitive impairment caused by Alzheimer's and other dementias. The work is published in the journal Alzheimer's&Dementia.
29/09/2023 - Institutional news
We are pleased to announce the official launch of the MARMetabolomics service, a pioneering initiative in the field of metabolomics at the Hospital del Mar Research Institute. MARMetabolomics is an advanced platform developed by the Applied Metabolomics Research Group (LIMA), which has extensive experience in the development of analytical methods for the determination of metabolites (small molecules involved in metabolic reactions that take place in biological systems) in both non-invasive (urine, breast milk, hair or cultures) and invasive (CSF, blood or tissues) matrices and their application in the field of health. The platform is a member of the European Infrastructure for Translational Medicine (EATRIS), the Spanish Metabolomics Network and the multidisciplinary center TECNIO, BAPP.
Més informació "Inauguration of the MARMetabolomics Service at Hospital del Mar Research Institute"
10/08/2023 - Press release
A team from the Hospital del Mar Research Institute has, for the first time, detected fetal DNA in the olfactory neuroepithelium of women who have given birth to a boy. A new study will now be launched, which will also analyze female fetal DNA. The team of researchers has been able to confirm that women with depression had much lower levels of cells from newborns than those who were not suffering from this disorder. This discovery paves the way to studying the DNA exchange between the mother and the fetus during pregnancy as a factor that protects women against depression, as well as its relationship with other psychiatric disorders.
28/07/2023 - Press release
Cannabis use disorder (CUD) affects over 14 million individuals in the US.? Despite the urgent need, there are no FDA-approved medications to treat CUD; behavioral treatments have shown limited benefit. AEF0117 is the first of a new pharmacologic class, type 1 cannabinoid receptor signaling-specific inhibitors (CB1-SSi), with a unique mechanism of action and greater safety and efficacy than prior generations of CB1 inhibitors.? In a phase 2a clinical study in volunteers with CUD, AEF0117 produced statistically significant reductions in the positive subjective and reinforcing effects of smoked cannabis.
15/06/2023 - Press release
A study published in iScience, spearheaded by the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Centre, part of the Pasqual Maragall Foundation, validates these tools for monitoring potential sufferers. Data was analysed from 56 volunteers who participated in the PENSA study, designed to determine whether it is possible to slow cognitive decline in stages prior to the onset of dementia through a combination of a lifestyle intervention programme and the consumption of a preparation based on a green tea component. It was possible to monitor the evolution of the cognitive functions of these people much more closely and continuously than with standard tests. This paves the way for the adaptation, practically in real time, of treatments that can be adjusted to changes in cognitive decline.
02/05/23 - Institutional news
The Anti-Doping Laboratory of Catalonia was visited last week by a delegation of the Board of Directors of the Catalan Association of Sports Directors (ACDE). ACDE is an association that brings together leaders, federations and professionals in the world of sport in Catalonia while providing them with the best tools to develop their role and promote excellence in the management and values of sport. The delegation was formed by Pere Sust (President of ACDE), Jordi Durá (Secretary), Francisco Sanahuja, Miquel Torres, Pilar Xifré, Manuel Martínez and Judith Martínez, all of them with extensive and recognized links to Catalan and international sports federations and organizations, and was received by the IMIM management and the Laboratory management. After an introduction of the activities of IMIM and the Laboratory, the attendees visited the Laboratory facilities
23/03/2023 - General information
The Associació Catalana de Gestors Esportius Professionals has recognized the international projection of the Laboratory. The Associació Catalana de Gestors Esportius Professionals (ACGEP) has awarded the Catalonia Prize for Sports Management on a national or international level to the Catalonian Anti-Doping Laboratory of the Hospital del Mar Medical Research Institute. The award recognizes the role of the Laboratory in projecting Catalonia to the world, its professionalism and its contribution to a cleaner sport. It was also highlighted that it is one of the thirty laboratories accredited in the world by the World Anti-Doping Agency to carry out doping controls on athletes, and that it works for clean sport in various national and international events.
23/02/2023 - Institutional news
The Associació Catalana de Dirigents de l'Esport (ACDE) awarded the distinction of Best Professional Leader to Dr. Rosa Ventura Alemany, director of the Anti-Doping Laboratory of Catalonia of the Hospital del Mar Institute of Medical Research. The distinction recognizes her work leading the Laboratory, one of the 30 laboratories accredited by the World Anti-Doping Agency in the world, and as coordinator of the Research Group on doping control in sport. It also recognizes the Laboratory's work in conducting doping controls for the 2018 Mediterranean Games in Tarragona, and in the management of athletes' biological passports. Finally, it recognizes the relevant scientific results achieved in recent years by the Research Group coordinated by Dr. Ventura Alemany.
18/01/2023 - General information
The Integrated Pharmacology and Systems Neurosciences Research Group of the Hospital del Mar Medical Research Institute has just published a study in Neurobiology of Disease, in which it highlights the role of the CDK5 protein as a possible marker of early psychosis. Furthermore, this protein is modulated by cannabis use. This paves the way for possible future treatments based on CDK5 expression.
Més informació "Possible biomarker for early psychosis identified"
20/12/2022 - General information
The Board of Trustees of the Spanish Psychiatry and Mental Health Foundation has chosen Dr. Víctor Pérez, head of the Psychiatry Department of the Hospital del Mar and coordinator of the Mental Health Research Group of the Hospital del Mar Medical Research Institute, as the new president of the organization. This appointment comes after Dr. Perez left his position as president of the executive committee of the Spanish Society of Psychiatry and Mental Health. As the highest representative of the foundation, Dr. Pérez will be responsible for representing the entity, chairing the meetings of its board of trustees and executing the agreements reached. The aim of its activity is to contribute to the knowledge, development and improvement of psychiatry and mental health and the disciplines that are linked to it.
Més informació "Dr. Víctor Pérez will chair the Spanish Foundation of Psychiatry and Mental Health."
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
